Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ensifentrine-Glycopyrrolate FDC in COPD
NCT07132983Phase 2Completed
- Sponsor
- Verona Pharma
- Start
- Oct 2025
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ensifentrine in chronic obstructive pulmonary disease (COPD), sponsored by Verona Pharma. Primary endpoints: Ensifentrine single dose area under the curve from time 0 to time t at 48 hours, Ensifentrine single dose area under the curve from time 0 extrapolated to infinity at 48 hours and 6 more. Started Oct 2025; status: completed.
02
Drugs
ensifentrine
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT07132983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07132983.